Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Novartis Bangladesh Limited (“NBL”) announced on Thursday that the agreement by Novartis AG to transfer its shares in NBL to ...
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
Radiant Pharmaceuticals Limited (RPL), one of the top healthcare solution providers in Bangladesh, is set to buy a majority ...
The U.S. Court of Appeals has reportedly ruled against Novartis (NVS) in its bid to prevent the U.S. launch of a generic ...
In a case-based competition, participants will be able to solve real-life problems in collaboration with experts from ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) on December 3 and set a price target of ...